Tandem Diabetes Care's stock plummeted 5.23% during intraday trading on Monday.
The decline followed analyst price target cuts from Barclays and Truist Securities. Barclays lowered its price target to $55 from $56, while Truist Securities cut its target to $31 from $35.
Despite Mizuho raising its price target to $24 from $22, the negative adjustments from other firms likely contributed to investor concerns, leading to the stock's drop.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments